Health Economics›Ovarian cancer›Second-line therapy for relapsed or recurrent disease platinum-sensitive

Second-line therapy for relapsed or recurrent disease platinum-sensitive

Ovarian cancer · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pegylated liposomal doxorubicin, Bevacizumab Variant #01	—	R 81 488	28d	11.8 mo	—	6	R 368 985 PFS proxy	3
Carboplatin and Paclitaxel (CP) and Olaparib Variant #01	—	R 75 702	21d	12.2 mo	—	6	R 217 317 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #01	—	R 48 987	28d	11.6 mo	42.2 mo	12	R 473 840 PFS proxy	3
Carboplatin and Gemcitabine (GCb) and Bevacizumab Variant #01	—	R 34 401	21d	11.7 mo	33.6 mo	6	R 206 404 PFS proxy	5
nab-Paclitaxel monotherapy Variant #01	—	R 16 043	28d	~5.5 mo	~11.5 mo	~2	~R 32 087 PFS proxy · indirect	2
Carboplatin and Pegylated liposomal doxorubicin Variant #03	—	R 13 338	28d	10.1 mo	21.4 mo	6	R 80 026 PFS proxy	4
Carboplatin and Docetaxel (DCb) Variant #06	—	R 5 501	21d	~4.7 mo	~22.3 mo	~6	~R 33 004 PFS proxy · indirect	4
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 4 414	21d	8.7 mo	32.9 mo	2	R 8 829 PFS proxy	5
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	—	~10.3 mo	~6	~R 23 595 PFS proxy · indirect	1
Cisplatin and Paclitaxel (TP) Variant #02	—	R 1 315	21d	—	29.0 mo	7	R 9 204 PFS proxy	1
Etoposide monotherapy Variant #01	—	R 1 231	28d	—	—	~6	~R 7 386 indirect	—
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	9.6 mo	29.0 mo	12	R 12 296 PFS proxy	8
Carboplatin monotherapy Variant #01	—	R 535	21d	5.8 mo	21.0 mo	2	R 1 070 PFS proxy	2
Rucaparib monotherapy Variant #01 Partial	—	—	28d	~20.2 mo	~27.7 mo	~2	—	7

14 of 14 regimens shown